MMAF (monomethyl auristatin F) is a new antimitotic auristatin derivative with a charged C-terminal phenylalanine residue. Mc-VC-PAB-MMAF is a thiol reactive derivative of MMAF that contains a cathepsin B cleavable valine-citrulline p-aminobenzylcarbamate linkage (VC-PAB). This product is a control ADC for any IgG type antibody labeled with MMAF, particularly any ADC made using CellMosaic's Antibody MMAF Conjugation Kit (Cat#: CM11425 and Cat#: CM11422). The product uses a human IgG1 subtype antibody that does not bind to the target. It has an average of 3-5 MMAF loaded on each antibody and can be used for accessing the effect of MMAF alone (non-specific toxicity). The product uses a very low endotoxin level antibody as a starting material (≤0.5 EU/mg by the LAL method). The preparation and purification are conducted under a pyrogen free environment. nnThe product is sold as 1 vial of 100 microgram (Cat# CM51101-100UG), 1 vial of 500 micrograms (Cat# CM51101-500UG), or 2 vials of 500 micrograms (Cat# CM51101-1MG). For bulk orders, please contact us for a quote.
